Chemistry:CA-170
From HandWiki
CA-170 is an investigational new drug being evaluated as an immune checkpoint inhibitor for the treatment of cancer. Developed by Aurigene Oncology, it is an orally available small molecule designed to selectively inhibit the immune checkpoint proteins PD-L1[1] and VISTA,[2] both of which are key negative regulators of T-cell activation implicated in cancer immune evasion.[3][4]
By targeting these immune pathways, CA-170 aims to restore and enhance the immune system's ability to recognize and eliminate tumor cells, offering the potential for improved anti-tumor responses across a variety of cancers.[4][5]
References
- ↑ "Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development". Frontiers in Immunology 13. 2022. doi:10.3389/fimmu.2022.752065. PMID 35585982.
- ↑ "VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses". RSC Medicinal Chemistry 12 (10): 1672–1679. October 2021. doi:10.1039/d1md00185j. PMID 34778768.
- ↑ "CA‑170". https://www.curis.com/pipeline/ca-170/.
- ↑ 4.0 4.1 "PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy". Communications Biology 4 (1). June 2021. doi:10.1038/s42003-021-02191-1. PMID 34103659.
- ↑ "Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas". Journal of Clinical Oncology 35 (15 suppl). 2017. doi:10.1200/JCO.2017.35.15_suppl.TPS3099.
Template:PD-1 and PD-L1 inhibitors
 |  |
